Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.

ABSTRACT:

Background

The sensitivity of myelocytomatosis oncogene (MYC) amplified medulloblastoma to class I histone deacetylase (HDAC) inhibition has been shown previously; however, understanding the underlying molecular mechanism is crucial for selection of effective HDAC inhibitors for clinical use. The aim of this study was to investigate the direct molecular interaction of MYC and class I HDAC2, and the impact of class I HDAC inhibition on MYC function.

Methods

Co-immunoprecipitation and mass spectrometry were used to determine the co-localization of MYC and HDAC2. Chromatin immunoprecipitation (ChIP) sequencing and gene expression profiling were used to analyze the co-localization of MYC and HDAC2 on DNA and the impact on transcriptional activity in primary tumors and a MYC ampl

SUBMITTER: Ecker J 

PROVIDER: S-EPMC7906057 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature